Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Jiangsu Nhwa In-licenses China Rights to Anti-Psychotic from Zysis

publication date: Mar 14, 2017
Jiangsu Nhwa Pharma acquired China rights to an extended-release form of aripiprazole (Ablify), an anti-psychotic drug being developed by Zysis of the UK. Ablify was indicated to treat schizophrenia, bipolar and major depressive disorder. Developed by Japan's Otsuka, its US patent expired in 2014. Zysis' product is a once-weekly oral formulation of the drug. Nhwa paid $500,000 upfront and will pay another $200,000 once Zysis transfers technology. Nhwa will also pay a non-disclosed royalty on sales. More details....

Stock Symbol: (SHZ: 2262)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital